Navigation Links
Fuisz Pharma Announces Acquisition of Key Anti Opiate Abuse Patent to Complement its Anti Opiate Abuse Platform
Date:7/12/2010

MIAMI, July 12 /PRNewswire/ -- Fuisz Pharma today announced that it has acquired a key issued patent (US 7,214,385 "Pharmaceutical Formulation Containing Dye" (invented by Dr. Thomas Gruber)).  This patent covers the use of dyes and staining agents in pharmaceutical dosage forms as a method to prevent the improper use of opiate derived drugs by visually demonstrating their misuse.

Fuisz Pharma President, Joseph Matus Fuisz commented: "The technology described in the acquired patent is highly complementary to the anti abuse portfolio that we previously announced.  Importantly, the Gruber patent enables us to offer strong, existing patent protection for our partners.   We thus believe that this acquisition significantly enhances the value of our anti abuse platform and gives us a very strong IP position in the prevention of opiate abuse."

Mr. Fuisz continued: "This acquisition is also complementary to our next generation technology to aid and abet the absorption of all dosage forms including the ability to bring forth a very novel methodology to specifically play a critical role in the opiate agonist/antagonist pas de deux. This methodology is applicable to all dosage forms."

Noted pharmaceutical inventor Richard C. Fuisz, M.D. (http://en.wikipedia.org/wiki/Richard_Carl_Fuisz) is one of the principals of Fuisz Pharma.

Fuisz Pharma is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma. Fuisz Pharma has its headquarters in Miami.  www.fuisz.com.


'/>"/>
SOURCE Fuisz Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
2. Fuisz Pharma Announces Novel Anti Abuse System for Opiates
3. FUISZ Announces Advances in Devices and Solid Dosage Form
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
(Date:9/6/2017)... SAN ANTONIO , Sept. 6, 2017  Robert ... as a Pinnacle Professional Member in recognition of his ... Dr. Szewc serves as a Nephrologist at the practice ... services, emergency medicine, kidney care and hypertension solutions. He ... over 20 years of career experience, as well as ...
(Date:9/6/2017)... INDIANAPOLIS , Sept. 6, 2017 Eli ... today it will present new data for galcanezumab and ... Congress of the International Headache Society (IHC) taking place ... Lilly will highlight new, long-term data from ... two doses of galcanezumab (120 mg and 240 mg) ...
Breaking Medicine Technology:
(Date:9/21/2017)... Payne, AL (PRWEB) , ... September 21, 2017 ... ... preparation provider with offices serving communities in northern Alabama and Georgia, is embarking ... breast cancer prevention by utilizing modern early detection methods. , US Breast ...
(Date:9/20/2017)... ... September 20, 2017 , ... FirstAlign ( http://www.firstalign.com ), ... latest Artificial Intelligence (AI) thinking, announced today the launch of its revamped web ... essential information that offers a more comprehensive understanding of the organization’s business and ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... a voice for people who have kidney disease. The theme “Describe a positive ... their stories. Entrants needed to meet only one qualification— to have been ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... much-anticipated fall event , Look Awesome This Autumn with CoolSculpting®. Scheduled for ... pricing and refreshments. , Mirror Mirror Beauty Boutique is Houston’s largest ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... innovation, the company recently unveiled a redesigned website. The new site – still ... of building owners, architects, contractors and other industry users that Garland serves. , ...
Breaking Medicine News(10 mins):